Amyloid Protein Identification : Paraffin, Mass Spectrometry

Available through our international laboratory collaboration with Mayo Clinic Laboratories

Overview

The Amyloid Protein Identification test uses mass spectrometry-based proteomic analysis on paraffin-embedded tissue to accurately identify the type of amyloid protein present.

This advanced test is increasingly incorporated into functional medicine tests, integrated medicine testing, and root cause testing protocols at leading functional health centres and longevity labs in Delhi / India.

Functional medicine practitioners in Delhi/India may recommend this test alongside holistic health tests, preventive longevity tests, or biological age test programs to provide comprehensive patient assessments, particularly when amyloidosis may impact overall health and wellness.

Correct classification of amyloidosis is critical for guiding treatment because different amyloid subtypes have distinct causes, prognoses, and management strategies. Traditional histopathology and Congo red staining confirm amyloid deposits, but mass spectrometry offers unmatched specificity in amyloid typing.

Amyloid Protein Identification Test Clinical Utility

This test is recommended for:

• Confirming and typing amyloid deposits in tissue samples
• Distinguishing between AL amyloidosis, ATTR amyloidosis, and other rare forms
• Supporting selection of targeted therapies based on amyloid subtype
• Avoiding misclassification that can lead to ineffective or harmful treatments

Integration of amyloid typing with functional medicine diagnostics, functional medicine tests, and integrated medicine testing allows a functional health centre or longevity lab in Delhi / India to provide precise treatment recommendations that complement holistic health tests, longevity tests, and biological age test assessments.

Specimen Requirements

• Specimen Type: Formalin-fixed, paraffin-embedded (FFPE) tissue block containing confirmed amyloid deposits (via Congo red or other staining)
• Alternative: 10–12 unstained slides at 5 μm thickness
• Preferred Sample Sources: Biopsy from affected organ (kidney, heart, fat pad, GI tract, etc.)

These protocols align with best practices at functional health centres and longevity labs in Delhi / India performing functional medicine diagnostics and root cause testing.

Amyloid Protein Identification Test Clinical Background

Amyloidosis represents a group of disorders caused by extracellular deposition of insoluble fibrillar proteins. Subtype identification is essential because:

• AL (light chain) amyloidosis requires urgent hematologic therapy
• ATTR (transthyretin) amyloidosis may respond to transthyretin stabilizers or RNA-silencing drugs
• Other hereditary or secondary amyloidoses may need disease-specific management

Mass spectrometry has emerged as the gold standard for amyloid typing, outperforming immunohistochemistry in accuracy and reproducibility.

This testing supports functional medicine diagnostics, holistic health tests, and functional medicine tests, complementing preventive longevity tests and biological age test programs under the supervision of a functional medicine practitioner in Delhi/India.

Turnaround Time

• Estimated: 7–10 business days from specimen receipt

Advantages of the Amyloid Protein Identification Test

• Gold-standard amyloid typing using advanced proteomics
• High diagnostic accuracy, even with small tissue samples
• Guides precise, personalized treatment planning
• Reduces risk of misdiagnosis and inappropriate therapy
• Complements functional medicine diagnostics, integrated medicine testing, and root cause testing at functional health centres and longevity labs in Delhi / India